Shafa Orthopedic Journal

Published by: Kowsar

Optimal Timing and Antibiotic Prophylaxis in Periprosthetic Joint Infection (PJI): Literature Review and World Consensus (Part Five)

Javad Parvizi 1 , * , Mohammad Ghazavi 2 and Members of Pre-Op Antibiotics Committee of the Consensus Meeting 3
Authors Information
1 Rothman Institute, Thomas Jefferson University, Philadelphia, USA
2 Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, IR Iran
3 William Arnold MD PhD; Katherine Belden MD, Goran Bicanic; Stefano Bini MD; Fabio Catani MD; Jiying Chen MD PhD; Mohammad Ghazavi MD FRCSC; Karine M. Godefroy MD; Erik Hansen MD; Paul Holham MD; Hamid Hosseinzadeh MD; Kang II Kim MD; Klaus Kirketerp-Moller MD; Lars Lidgren MD PhD; Jian Hao Lin MD; Jess H. Lonner MD; Christopher Moore MD; Panayiotis Papagelopoulos MD; Lazaros Poultsides MD MSc PhD; Khalid Saleh MD MSC FRCSC MHCM; Julia V. Salmon MD; Edward Schwarz PhD; Randi Silibovsky MD (US); Jose Stuyck MD; Markus Vogt MD (International); Annette W. Dahl MD; Koji Yamada MD
Article information
  • Shafa Orthopedic Journal: February 28, 2016, 3 (1); e5035
  • Published Online: February 20, 2016
  • Article Type: Review Article
  • Received: December 13, 2015
  • Accepted: December 19, 2015
  • DOI: 10.17795/soj-5035

To Cite: Parvizi J, Ghazavi M, Committee of the Consensus Meeting M O P A. Optimal Timing and Antibiotic Prophylaxis in Periprosthetic Joint Infection (PJI): Literature Review and World Consensus (Part Five), Shafa Ortho J. 2016 ;3(1):e5035. doi: 10.17795/soj-5035.

Abstract
Copyright: Copyright © 0, Shafa Orthopedic Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
References
  • 1. Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers W, American Academy of Orthopaedic S, American Association of Critical Care N, American Association of Nurse A, et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004; 38(12): 1706-15[DOI][PubMed]
  • 2. Zanetti G, Giardina R, Platt R. Intraoperative redosing of cefazolin and risk for surgical site infection in cardiac surgery. Emerg Infect Dis. 2001; 7(5): 828-31[DOI][PubMed]
  • 3. Zanetti G, Goldie SJ, Platt R. Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery. Emerg Infect Dis. 2001; 7(5): 820-7[DOI][PubMed]
  • 4. Prokuski L. Prophylactic antibiotics in orthopaedic surgery. J Am Acad Orthop Surg. 2008; 16(5): 283-93[PubMed]
  • 5. Fletcher N, Sofianos D, Berkes MB, Obremskey WT. Prevention of perioperative infection. J Bone Joint Surg Am. 2007; 89(7): 1605-18[DOI][PubMed]
  • 6. Dellinger EP, Gross PA, Barrett TL, Krause PJ, Martone WJ, McGowan JJ, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. The Infectious Diseases Society of America. Infect Control Hosp Epidemiol. 1994; 15(3): 182-8[PubMed]
  • 7. Ohge H, Takesue Y, Yokoyama T, Murakami Y, Hiyama E, Yokoyama Y, et al. An additional dose of cefazolin for intraoperative prophylaxis. Surg Today. 1999; 29(12): 1233-6[PubMed]
  • 8. Scher KS. Studies on the duration of antibiotic administration for surgical prophylaxis. Am Surg. 1997; 63(1): 59-62[PubMed]
  • 9. Shapiro M, Munoz A, Tager IB, Schoenbaum SC, Polk BF. Risk factors for infection at the operative site after abdominal or vaginal hysterectomy. N Engl J Med. 1982; 307(27): 1661-6[DOI][PubMed]
  • 10. Polk HJ, Trachtenberg L, Finn MP. Antibiotic activity in surgical incisions. The basis of prophylaxis in selected operations. JAMA. 1980; 244(12): 1353-4[PubMed]
  • 11. Morita S, Nishisho I, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, et al. The significance of the intraoperative repeated dosing of antimicrobials for preventing surgical wound infection in colorectal surgery. Surg Today. 2005; 35(9): 732-8[DOI][PubMed]
  • 12. Swoboda SM, Merz C, Kostuik J, Trentler B, Lipsett PA. Does intraoperative blood loss affect antibiotic serum and tissue concentrations? Arch Surg. 1996; 131(11): 1165-71[PubMed]
  • 13. Markantonis SL, Kostopanagiotou G, Panidis D, Smirniotis V, Voros D. Effects of blood loss and fluid volume replacement on serum and tissue gentamicin concentrations during colorectal surgery. Clin Ther. 2004; 26(2): 271-81[PubMed]
  • 14. Klekamp JW, DiPersio D, Haas DW. No influence of large volume blood loss on serum vancomycin concentrations during orthopedic procedures. Acta Orthop Scand. 1999; 70(1): 47-50[PubMed]
  • 15. Meter JJ, Polly DJ, Brueckner RP, Tenuta JJ, Asplund L, Hopkinson WJ. Effect of intraoperative blood loss on the serum level of cefazolin in patients managed with total hip arthroplasty. A prospective, controlled study. J Bone Joint Surg Am. 1996; 78(8): 1201-5[PubMed]
  • 16. Polly DJ, Meter JJ, Brueckner R, Asplund L, van Dam BE. The effect of intraoperative blood loss on serum cefazolin level in patients undergoing instrumented spinal fusion. A prospective, controlled study. Spine (Phila Pa 1976). 1996; 21(20): 2363-7[PubMed]
  • 17. Gilbert DN. The Sanford guide to antimicrobial therapy. 2002;
  • 18. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis. 1997; 25(1): 112-8[PubMed]
  • 19. Leader WG, Tsubaki T, Chandler MH. Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients. Am J Hosp Pharm. 1994; 51(17): 2125-30[PubMed]
  • 20. Janson B, Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis. 2012; 25(6): 634-49[DOI][PubMed]
  • 21. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995; 39(6): 605-9[PubMed]
  • 22. Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J. 2012; 42(1): 23-9[DOI][PubMed]
  • 23. Ho VP, Nicolau DP, Dakin GF, Pomp A, Rich BS, Towe CW, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmt). 2012; 13(1): 33-7[DOI][PubMed]
  • 24. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009; 49(3): 325-7[DOI][PubMed]
  • 25. Traynor AM, Nafziger AN, Bertino JJ. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother. 1995; 39(2): 545-8[PubMed]
  • 26. Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery. 1989; 106(4): 750-6[PubMed]
  • 27. van Kralingen S, Taks M, Diepstraten J, van de Garde EM, van Dongen EP, Wiezer MJ, et al. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol. 2011; 67(10): 985-92[DOI][PubMed]
  • 28. Edmiston CE, Krepel C, Kelly H, Larson J, Andris D, Hennen C, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Surgery. 2004; 136(4): 738-47[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader